Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beyond COVID-19 Spending Growth, Biosimilars Slowed Growth In Other Categories

IQVIA Finds Non-COVID Drug Spending Up Just 5%

Executive Summary

The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.

You may also be interested in...



BioNTech Buoyant On CAR-T/CARVac Combo Data

CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.

Moderna Sees Key Role For Respiratory Vaccines As COVID-19 Goes Endemic

The company anticipates another year of big sales for its COVID-19 vaccine, but is also touting a pipeline of 44 programs in development, with oncology and possibly rare disease data this year.

2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy

Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel